The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
_256_384.jpg)
The transaction is expected to be completed within one month from the signing of the definitive agreements.
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
PET sheets are widely recognised for their superior clarity, strength, and barrier properties
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Subscribe To Our Newsletter & Stay Updated
